First human trial launches for experimental drug ABBV-1451
NCT ID NCT07570147
First seen May 10, 2026 · Last updated May 14, 2026 · Updated 1 time
Summary
This early-stage study tests a new drug called ABBV-1451 in healthy volunteers to see how safe it is and how the body processes it. About 90 adults, including Japanese and Han Chinese participants, will receive a single dose. The goal is to gather initial safety and drug-level information before moving to patient studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Acpru /Id# 282128
Grayslake, Illinois, 60030, United States
Conditions
Explore the condition pages connected to this study.